FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3

Xifeng Xiong, Xudong Lai, Jinli Zhang, Qingqi Meng, Pengzhen Wang, Shengnan Qin, Wei Liu, Yongxuan Wang, Zhuo Yao, Di Wang, Xiaojian Li, Zhihe Liu, Haixiong Miao

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Worldwide, ovarian cancer (OC) is the seventh common cancer and the second most common cause of cancer death in women. Due to high rates of relapse, there is an urgent need for the identification of new targets for OC treatment. The far-upstream element binding protein 1 (FBP1) and enhancer of zeste homolog 2 (EZH2) are emerging proto-oncogenes that regulate cell proliferation and metastasis. In the present study, Oncomine data analysis demonstrated that FBP1 was closely associated with the development of OC, and The Cancer Genome Atlas (TCGA) data analysis indicated that there was a positive correlation between FBP1 and EZH2 in ovarian tissues. Moreover, we found that FBP1 knockdown suppressed tumor formation in nude mice and cisplatin resistance of OC cells, but the role of FBP1 in the cisplatin resistance of OC cells remained unclear. In addition, we verified physical binding between FBP1 and EZH2 in OC cells, and we demonstrated that FBP1 knockdown enhanced cisplatin cytotoxicity in OC cells and down-regulated EZH2 expression and trimethylation of H3K27. These results suggested that FBP1 increases cisplatin resistance of OC cells by up-regulating EZH2/H3K27me3. Thus, FBP1 is a prospective novel target for the development of OC treatment.

Original languageEnglish
Article numberBSR20221002
Number of pages16
JournalBioscience Reports
Volume42
Issue number9
DOIs
Publication statusPublished - 7 Sept 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3'. Together they form a unique fingerprint.

Cite this